BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34759345)

  • 1. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
    Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
    Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
    Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
    bioRxiv; 2024 May; ():. PubMed ID: 38798502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
    Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
    Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
    Damodharan S; Helgager J; Puccetti D
    Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
    Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
    Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.
    Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR
    Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
    Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
    Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
    Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
    Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
    Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
    Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
    Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.